The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

• Main Authors: Stewart Coats, Andrew J., Srinivasan, Venkatesan, Surendran, Jayaraman, Chiramana, Haritha, Vangipuram, Shankar R. K. G., Bhatt, Nirajkumar N., Jain, Minish, Shah, Sandip, Ali, Irfhan A. B. H., Fuang, Ho G., Mat Hassan, Mohd. Zailani, Beadle, John, Tilson, Julia, Kirwan, Bridget-Anne, Anker, Stefan D.
• Format: Article
• Language: English
• Published: Springer 2011
• Subjects: R Medicine (General)
• Online Access: http://irep.iium.edu.my/18416/1/13539_2011_Article_46.pdf; http://irep.iium.edu.my/18416/; http://dx.doi.org/10.1007/s13539-011-0046-2

Aims Cachexia, the wasting disorder associated with a wide range of serious illnesses including cancer, is a major cause of morbidity and mortality. There is currently no widely approved therapeutic agent for treating or preventing cancer-associated cachexia. Colorectal cancer and nonsmall cell l...